The lower risk of insulin initiation after the reform most likely reflects the changing treatment practices of type 2 diabetes and newer non-insulin antidiabetic medicines entering clinical practice also in Finland (Järvinen et al., 2016; Niskanen & Laine, 2020). This evidence concerns the gene INS and type 2 diabetes mellitus.